Creating new drugs to treat neuropathic pain more effectively
Development of Pathology-activated Drugs for Treatment of Neuropathic Pain
This study is working on new medications that aim to better relieve nerve pain for people who often find their current treatments aren't helping enough, by creating drugs that target pain directly and reduce side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10984975 on NIH RePORTER |
What this research studies
This research focuses on developing innovative drugs that can better address neuropathic pain, which is often inadequately treated by current therapies. The approach involves designing new prodrugs that release an active compound specifically at sites of pain, minimizing side effects and improving tolerability. By targeting multiple biochemical pathways involved in pain, the research aims to enhance the effectiveness of treatment for patients suffering from chronic pain conditions. The study will utilize advanced techniques to ensure that these new drugs are both safe and effective.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing chronic neuropathic pain who have not found relief with existing treatments.
Not a fit: Patients with acute pain conditions or those who do not have neuropathic pain may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective pain relief for patients suffering from neuropathic pain with fewer side effects.
How similar studies have performed: Previous research has shown promise in developing targeted drug delivery systems for pain management, indicating potential success for this novel approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Grace, Peter M — University of Tx Md Anderson Can Ctr
- Study coordinator: Grace, Peter M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.